GSK Announces Up to $800 Million Investment for U.S. Manufacturing Site

A fresh investment from UK pharmaceutical company GSK will be providing up to $800 million to grow U.S. facilities. The plan is to expand its footprint and upgrade its current manufacturing technology so it can fulfill needs for specific vaccines and drugs. 

This is the largest investment GSK has made towards manufacturing in America. 

The current GSK plant in Marietta, PA is set to receive a major transformation that will double its square footage and the amount of product it can produce and hold. There are also plans for the company to create a second facility, which will primarily focus on producing drugs for clinical trials. 

While growth is top of mind, so is sustainability. Both plants are being constructed with green practices in mind, such as the inclusion of solar panels, smart monitoring systems for utilities, and both AI and robot-enabled services and machines that can better predict maintenance and system needs. The testing plant will also have a LEED Silver certification. 

Keeping Up with Medical Advances

There has been a marked increase in demand for numerous drugs and vaccines, particularly sterile liquid vaccines and vaccines made with multiple antigen presenting systems (MAPS)—which the new facility can produce. GSK is also targeting several specific diseases, including shingles, shigella, RSV, meningitis, and the flu. 

The company plans for the upgraded Marietta factory to be up and running by the end of 2027 and the trial facility to be functional towards the end of 2028. It also aims to create over 200 new jobs for Americans.

The Rebirth of Domestic Manufacturing

The last few years have marked a new era for American manufacturing. But injecting financial support into American facilities isn’t new for GSK. Since 2017, the company has provided around $1.3 billion for manufacturing in the U.S.

It is just one example that can be parsed from the multitude of governmental bodies and private and public companies that are bought into igniting the renaissance for U.S. production. This includes a push for domestic creation of semiconductors, batteries, sustainable energy components, and medicine. The White House reported that the private sector alone has poured $900 million into manufacturing and power to see this growth happen.

Impact of Foreign Investment 

While the point for these changes is to bring manufacturing production back into the country, it doesn’t mean companies won’t accept help from foreign investors. In fact, this is one such strategy many corporations are embracing in order to stay competitive while keeping production within the U.S. 

With the CHIPS & Science Act driving a good portion of investments and law-based support and visibility, companies such as GSK that may hail from outside of America are proving to be pivotal in driving this shift and providing financial backing, creating additional jobs, and boosting growth. 

Image Credit: Shutterstock/JHVEPhoto